Geron Announces NCCN Guidelines Update for RYTELO™ in Lower-Risk MDS

Geron Corporation (Nasdaq: GERN) has announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include RYTELO™ (imetelstat) as a recommended treatment for symptomatic anemia in lower-risk myelodysplastic syndromes (MDS). The updated guidelines categorize RYTELO…

Read MoreGeron Announces NCCN Guidelines Update for RYTELO™ in Lower-Risk MDS

Schrödinger Launches Initiative to Broaden Computational Tools for Predictive Toxicology

Schrödinger, Inc. (Nasdaq: SDGR), renowned for its physics-based computational platform, is launching a new initiative to enhance early-stage drug discovery by predicting toxicology risks. This project aims to improve drug development candidates by minimizing the risk of adverse effects from…

Read MoreSchrödinger Launches Initiative to Broaden Computational Tools for Predictive Toxicology

Amprion Debuts Next-Gen SAAmplify™ Panels for Neurodegenerative Diagnosis at AAIC 2024

Amprion, a leader in advancing the diagnosis of neurodegenerative disorders through seed amplification testing, is unveiling its new line of cerebrospinal fluid (CSF) biomarker panels under the SAAmplify brand. These panels provide physicians and patients with the most comprehensive biomarkers…

Read MoreAmprion Debuts Next-Gen SAAmplify™ Panels for Neurodegenerative Diagnosis at AAIC 2024